149 related articles for article (PubMed ID: 10323334)
1. Determination of N-acetylation phenotyping in a Greek population using caffeine as a metabolic probe.
Asprodini EK; Zifa E; Papageorgiou I; Benakis A
Eur J Drug Metab Pharmacokinet; 1998; 23(4):501-6. PubMed ID: 10323334
[TBL] [Abstract][Full Text] [Related]
2. A population and family study of N-acetyltransferase using caffeine urinary metabolites.
Bechtel YC; Bonaiti-Pellie C; Poisson N; Magnette J; Bechtel PR
Clin Pharmacol Ther; 1993 Aug; 54(2):134-41. PubMed ID: 8354022
[TBL] [Abstract][Full Text] [Related]
3. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes.
Vincent-Viry M; Pontes ZB; Gueguen R; Galteau MM; Siest G
Genet Epidemiol; 1994; 11(2):115-29. PubMed ID: 8013893
[TBL] [Abstract][Full Text] [Related]
4. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity.
Cribb AE; Isbrucker R; Levatte T; Tsui B; Gillespie CT; Renton KW
Pharmacogenetics; 1994 Jun; 4(3):166-70. PubMed ID: 7920698
[TBL] [Abstract][Full Text] [Related]
5. Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure.
Jetter A; Kinzig-Schippers M; Illauer M; Hermann R; Erb K; Borlak J; Wolf H; Smith G; Cascorbi I; Sörgel F; Fuhr U
Eur J Clin Pharmacol; 2004 Mar; 60(1):17-21. PubMed ID: 14747882
[TBL] [Abstract][Full Text] [Related]
6. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
[TBL] [Abstract][Full Text] [Related]
7. Acetylation polymorphism of caffeine in a Japanese population.
Hashiguchi M; Ebihara A
Clin Pharmacol Ther; 1992 Sep; 52(3):274-6. PubMed ID: 1526084
[TBL] [Abstract][Full Text] [Related]
8. Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?
Jetter A; Kinzig M; Rodamer M; Tomalik-Scharte D; Sörgel F; Fuhr U
Eur J Clin Pharmacol; 2009 Apr; 65(4):411-7. PubMed ID: 19082994
[TBL] [Abstract][Full Text] [Related]
9. Concordance between the deduced acetylation status generated by high-speed: real-time PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay.
Rihs HP; John A; Scherenberg M; Seidel A; Brüning T
Clin Chim Acta; 2007 Feb; 376(1-2):240-3. PubMed ID: 17011540
[TBL] [Abstract][Full Text] [Related]
10. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
[TBL] [Abstract][Full Text] [Related]
11. N-Acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a White population.
Djordjevic N; Carrillo JA; Ueda N; Gervasini G; Fukasawa T; Suda A; Jankovic S; Aklillu E
J Clin Pharmacol; 2011 Jul; 51(7):994-1003. PubMed ID: 20801937
[TBL] [Abstract][Full Text] [Related]
12. [The acetylator polymorphism in a Khmer population: clinical consequences].
Bechtel YC; Bechtel PR; Lelouët H; Choisy H; Dy NR
Therapie; 2001; 56(4):409-13. PubMed ID: 11677864
[TBL] [Abstract][Full Text] [Related]
13. NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios.
Nyéki A; Buclin T; Biollaz J; Decosterd LA
Br J Clin Pharmacol; 2003 Jan; 55(1):62-7. PubMed ID: 12534641
[TBL] [Abstract][Full Text] [Related]
14. Determination of acetylator phenotype in Caucasians with caffeine.
Hildebrand M; Seifert W
Eur J Clin Pharmacol; 1989; 37(5):525-6. PubMed ID: 2598993
[TBL] [Abstract][Full Text] [Related]
15. A simplified and rapid test for acetylator phenotyping by use of the peak height ratio of two urinary caffeine metabolites.
el-Yazigi A; Chaleby K; Martin CR
Clin Chem; 1989 May; 35(5):848-51. PubMed ID: 2566399
[TBL] [Abstract][Full Text] [Related]
16. Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators.
Al-Ahmad MM; Amir N; Dhanasekaran S; John A; Abdulrazzaq YM; Ali BR; Bastaki S
Ann Hum Genet; 2017 Sep; 81(5):190-196. PubMed ID: 28653770
[TBL] [Abstract][Full Text] [Related]
17. Acetylation phenotypes and biological variation in a French Caucasian population.
Pontes ZB; Vincent-Viry M; Gueguen R; Galteau MM; Siest G
Eur J Clin Chem Clin Biochem; 1993 Feb; 31(2):59-68. PubMed ID: 8467011
[TBL] [Abstract][Full Text] [Related]
18. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells.
Frederickson SM; Messing EM; Reznikoff CA; Swaminathan S
Cancer Epidemiol Biomarkers Prev; 1994; 3(1):25-32. PubMed ID: 8118381
[TBL] [Abstract][Full Text] [Related]
19. Caffeine acetylator phenotyping during maturation in infants.
Pariente-Khayat A; Pons G; Rey E; Richard MO; D'Athis P; Moran C; Badoual J; Olive G
Pediatr Res; 1991 May; 29(5):492-5. PubMed ID: 1896253
[TBL] [Abstract][Full Text] [Related]
20. Relationship between metabolic phenotype of N-acetylation and bladder cancer.
Cui X; Guo R; Xu Z; Wang B; Li C
Chin Med J (Engl); 2000 Apr; 113(4):303-5. PubMed ID: 11775223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]